Evidence map›Paper›PMID 15338086›Full record

ArticleEuropean journal of clinical pharmacology2004

Patterns and correlates of benzodiazepine use in the French general population.

Rajaa Lagnaoui, Fanny Depont, Annie Fourrier, Abdelillah Abouelfath, Bernard Bégaud, Hélène Verdoux, Nicholas Moore

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06446349 (Impact of Identification and Brief Motivational Intervention in Dispensing Pharmacies), which is not on this map. Cited by 44 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 3 pooled it
6.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06446349 narecruitingnot on this mapstarted 2024, after this paper: background citation

Impact of Identification and Brief Motivational Intervention in Dispensing Pharmacies (BMI) on the Deprescription of Benzodiazepines and Related Substances in Adult Chronic Drug Users

TypeinterventionalSponsorUniversity Hospital, GrenobleRan2024 to 2026Enrolled300ConditionsBenzodiazepine WithdrawalArmsBrief motivational intervention
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 156 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Opioid and benzodiazepine use in end-stage renal disease: a systematic review.Clinical journal of the American Society of Nephrology : CJASN · 2011
    Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Long-term benzodiazepine prescriptions in community psychiatry clinics.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rajaa LagnaouiDépartement de Pharmacologie, EA 3676, IFR 99, Université Victor Segalen, Bordeaux 2, 33076 Bordeaux, France.
Fanny Depont
Annie Fourrier
Abdelillah Abouelfath
Bernard Bégaud
Hélène Verdoux
Nicholas Moore
Université de Bordeaux · FRCentre Hospitalier Charles Perrens · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the prevalence of current use of benzodiazepines (BZDs) and related drugs in the French general population and factors associated with this use.

methodsNational cross-sectional telephone survey conducted between 25 April 2001 and 8 May 2001 in a representative sample of non-institutionalized adults of BZD use and duration, prescriber specialty, socio-demographic data and mood and anxiety disorders, using a structured diagnostic interview.

resultsThe prevalence of current use of BZD was 7.5%. It was higher among women (9.7%) than men (5.2%). It increased with age and was higher in the jobless (10.9). Duration of BZD use was more than 6 months in 75.9% of users and increased with age. Of the 711 (17.7%) subjects with at least one mood or anxiety disorder, 122 (17%) used BZD compared with 180 (5.5%) of the 3296 subjects without mood or anxiety disorders. In multivariate analysis, factors associated with BZD use were age [odds ratio (OR): 3.6; 95% confidence interval (CI) 2.0-5.6], 6.5 (4.1-10.3) and 10.9 (6.9-17.1), respectively, for ages 35-44 years, 45-59 years and over 60 years compared with below 34 years, female gender (OR: 1.7; 95% CI 1.3-2.1), anxiety only (OR: 2.2; 95% CI 1.5-3.2), mood disorder only (OR: 4.4; 95% CI 2.7-7.1) or both mood and anxiety disorders (OR: 8.8; 95% CI 5.9-12.6).

conclusionDespite precautions, warnings and attempts to limit use, there remains a high proportion of long-term BZD users in the general French population, especially in the elderly. Our findings add to the weight of opinion that messages concerning proper use of BZDs certainly need to be clarified and amplified.

Indexed as

AdultAgedAged, 80 and overAge DistributionAnti-Anxiety AgentsAnxiety DisordersBenzodiazepinesCross-Sectional StudiesFemaleFranceHumansMaleMiddle AgedPharmacoepidemiologyPopulation SurveillancePrevalenceAnti-Anxiety AgentsBenzodiazepines

Identifiers

PMID15338086
OpenAlexW2015725434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.